Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2010-09-21
2011-11-22
Ward, Paul V. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S277000, C546S255000, C546S268100
Reexamination Certificate
active
08063072
ABSTRACT:
Compounds having the formula I wherein R1, R2, R3, R4, and R5are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
REFERENCES:
patent: 2010/0010017 (2010-01-01), Liu et al.
patent: 2010/0021423 (2010-01-01), Brameld et al.
patent: 2010/0081658 (2010-04-01), Chin et al.
patent: 2010/0111900 (2010-05-01), Li et al.
patent: 2010/0158860 (2010-06-01), Steiner et al.
patent: WO 01/85172 (2001-11-01), None
patent: WO 01/85172 (2001-11-01), None
patent: WO 2004/041818 (2004-05-01), None
patent: WO 2009/032116 (2009-03-01), None
patent: WO 2009/032123 (2009-03-01), None
patent: WO 2009/032123 (2009-03-01), None
patent: WO 2009/032123 (2009-03-01), None
patent: WO 2009-032125 (2009-03-01), None
patent: WO 2009/039127 (2009-03-01), None
patent: WO 2009/039134 (2009-03-01), None
patent: WO 2009/039135 (2009-03-01), None
patent: WO 2009/064848 (2009-05-01), None
patent: WO 2009/064852 (2009-05-01), None
patent: WO 2010/111436 (2010-09-01), None
patent: WO 2010/111437 (2010-09-01), None
Fidalgo Javier de Vincente
Li Jim
Schoenfeld Ryan Craig
Talamas Francisco Xavier
Buckwalter Brian L.
Roche Palo Alto LLC
Ward Paul V.
LandOfFree
Heterocyclic antiviral compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic antiviral compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic antiviral compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4279734